In 201 consecutive patients biopsied for suspected NASH, liver damage has been quantified by NAFLD activity score, circulating PCSK9 by ELISA, and hepatic mRNA by qRT–PCR in 76 of the patients. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.